相关实验视频
Updated: May 11, 2026

07:46
Assessing Endothelial Vasodilator Function with the Endo-PAT 2000
Published on: October 16, 2010
组织内甲蛋白转化酶活性与冠状动脉疾病中心血管风险因素相关
F Ruschitzka1, U Moehrlen, T Quaschning
1Cardiology, University Hospital and Cardiovascular Research, Institute of Physiology, University of Zürich, Switzerland.
Circulation
|September 7, 2000
概括
血管内甲蛋白转化酶 (ECE) 的活性与心血管风险因素有关. 较低的ECE活性与较高的LDL胆固醇和血压相关,这表明冠状动脉疾病在进展中发挥了作用.
科学领域:
- 心血管生物学 心血管生物学
- 酶学 是一种酶学.
- 血管生理学 血管生理学
背景情况:
- 内分泌蛋白转化酶 (ECE) 对于产生内分泌蛋白-1 (ET-1) 是至关重要的.
- 在心血管疾病 (CVD) 病理生理学中ECEs的特定作用尚未完全理解.
研究的目的:
- 研究冠状动脉疾病 (CAD) 患者血管ECE活动和心血管风险因素之间的关系.
- 探索低密度脂蛋白 (LDL) 和氧化LDL对人类内皮细胞中ECE-1蛋白水平的影响.
主要方法:
- 在CAD患者的内部乳腺动脉 (IMA) 和软静脉 (SV) 中检查了对大内甲蛋白-1 (bigET-1) 和ET-1的血管反应性.
- 评估了血管ECE活性,组织bigET-1和ET-1水平以及ECE-1蛋白质表达.
- 与血清LDL水平,血压和纤维素原相关联的ECE活性.
主要成果:
- 在IMA中,血管ECE活性与血清LDL水平和血压相反相关.
- 纤维素素在IMA和SV中与ECE活性正相关.
- LDL和氧化的LDL降低了人类IMA内皮细胞中的ECE-1蛋白水平.
结论:
- 血管ECE活性与LDL水平和血压相反相关,并且与人体血管组织中的纤维素素积极相关.
- 在患有CAD的患者中,ECE-1活性可能在调节心血管风险方面发挥重要作用.
相关概念视频
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Coronary Artery Disease I: Introduction
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Atherosclerosis I: Introduction
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

